Randomized, Double Blind, Active-controlled, Parallel Study to Analyse Effects of the Combination of Aliskiren and Valsartan on the Vascular Structure and Function of Retinal Vessels

Trial Profile

Randomized, Double Blind, Active-controlled, Parallel Study to Analyse Effects of the Combination of Aliskiren and Valsartan on the Vascular Structure and Function of Retinal Vessels

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Nov 2016 Results assessing effect of Valsartan on retinal capillary rarefaction in hypertensive patients (n=150) using patients data from this and other two trials (NCT00152698 and NCT01319344) published in the Journal of Clinical Hypertension (Greenwich)
    • 05 Aug 2015 New trial record
    • 15 Jun 2015 Primary endpoint has been met. (To investigate the combined effect of aliskiren and valsartan on vascular structure, assessed by wall to lumen ratio of retinal arterioles, in hypertensive patients.), according to an abstract presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top